Grünenthal considers funding options after reports of scrapped leveraged debt sale
![pills adobe stock 575x375 pharmaceuticals](https://assets.euromoneydigital.com/dims4/default/d06bb47/2147483647/strip/true/crop/575x374+0+0/resize/840x546!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2Fd7%2F64%2Ff4d57e446b58f70d1071e128f337%2Fpills-adobe-stock-575x375-pharmaceuticals.jpg)
Grünenthal, the German pain relief medicine maker, has extended the maturities on €535m of term loan facilities, telling GlobalCapital it is open to various financing options, after a press report saying investors had shunned a new euro leveraged loan.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: